A detailed history of State Street Corp transactions in Milestone Pharmaceuticals Inc. stock. As of the latest transaction made, State Street Corp holds 19,311 shares of MIST stock, worth $33,214. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19,311
Previous 18,923 2.05%
Holding current value
$33,214
Previous $24,000 20.83%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.29 - $1.65 $500 - $640
388 Added 2.05%
19,311 $29,000
Q1 2024

May 15, 2024

SELL
$1.4 - $2.2 $3,763 - $5,913
-2,688 Reduced 12.44%
18,923 $33,000
Q2 2023

Aug 14, 2023

SELL
$2.85 - $4.4 $1,105 - $1,707
-388 Reduced 1.76%
21,611 $61,000
Q1 2023

May 15, 2023

SELL
$3.14 - $4.2 $295 - $394
-94 Reduced 0.43%
21,999 $86,000
Q4 2022

Feb 14, 2023

BUY
$3.53 - $9.5 $342 - $921
97 Added 0.44%
22,093 $87,000
Q3 2022

Nov 15, 2022

BUY
$5.86 - $9.43 $2,273 - $3,658
388 Added 1.8%
21,996 $202,000
Q2 2022

Aug 15, 2022

SELL
$5.13 - $7.37 $995 - $1,429
-194 Reduced 0.89%
21,608 $128,000
Q1 2022

May 16, 2022

BUY
$4.1 - $8.24 $3,976 - $7,992
970 Added 4.66%
21,802 $140,000
Q4 2021

Feb 14, 2022

BUY
$5.47 - $7.13 $2,100 - $2,737
384 Added 1.88%
20,832 $136,000
Q3 2021

Nov 15, 2021

BUY
$5.28 - $6.29 $20,180 - $24,040
3,822 Added 22.99%
20,448 $117,000
Q2 2021

Aug 16, 2021

SELL
$5.22 - $6.11 $2,035 - $2,382
-390 Reduced 2.29%
16,626 $91,000
Q4 2020

Feb 16, 2021

SELL
$5.57 - $7.66 $3,041 - $4,182
-546 Reduced 3.11%
17,016 $114,000
Q3 2020

Nov 10, 2020

BUY
$3.34 - $9.8 $58,657 - $172,107
17,562 New
17,562 $129,000

Others Institutions Holding MIST

About Milestone Pharmaceuticals Inc.


  • Ticker MIST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,010,900
  • Market Cap $51.6M
  • Description
  • Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...
More about MIST
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.